TESARO (TSRO) : The consensus on TESARO (TSRO) based on 12 analyst recommendation on the company stock is 1.42, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 9 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
TESARO (TSRO) has been rated by 10 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $114 and the lowest price target forecast is $80. The average forecast of all the analysts is $101.8 and the expected standard deviation is $9.07.
For the current week, the company shares have a recommendation consensus of Buy. Also, Bank of America initiates coverage on TESARO (NASDAQ:TSRO). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. The rating by the firm was issued on August 30, 2016.
TESARO (NASDAQ:TSRO): The stock opened at $87.03 and touched an intraday high of $88.425 on Wednesday. During the day, the stock corrected to an intraday low of $86.52, however, the bulls stepped in and pushed the price higher to close in the green at $88.18 with a gain of 1.64% for the day. The total traded volume for the day was 546,038. The stock had closed at $86.76 in the previous trading session.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.